QALYs for COVID-19: A Comparison of US EQ-5D-5L Value Sets

Abstract

Background In economic evaluations, quality-adjusted life-years (QALYs) can serve as a unit of measurement for disease burden. Obtaining QALY values for COVID-19 presents a challenge owing to the availability of two US EQ-5D-5L value sets and the potentially asymptomatic presentation of the disease. The first value set was completed allowing for the discounting of future health outcomes while the second value set is undiscounted. Objective The objective of this study was to compare the distribution of QALY values using a national survey and the two published value sets; and to estimate the association between COVID-19 outcomes and QALY losses. Methods Between 9 and 11 November, 2020, 1153 US adults completed the EQ-5D-5L instrument (five items and a visual analog scale) as well as self-reported their demographics, COVID-19 symptoms, and memberships to populations that are at risk of COVID-19 infection. The two US value sets were applied to the EQ-5D-5L responses to produce QALY values. We estimated the mean QALYs by visual analog scale decile and a generalized linear model of COVID-19 outcomes. Results The discounted values are higher than the undiscounted values for each visual analog scale decile owing to methodological differences. Persons at increased risk, with a fever in the past day, and with one or more other symptoms have significantly greater QALY losses ( p < 0.01). Overall, non-institutionalized individuals at risk of symptomatic clinical COVID-19 equal 0.68 for the 2016 value set (95% confidence interval 0.49–0.87) and 0.10 for the 2017 value set (95% confidence interval − 0.31 to 0.51) QALYs. Conclusions Multiple studies have shown that decision makers discount future health outcomes, which increase QALY values. This study confronts the practical implications of these methodological advances for use in COVID-19 economic evaluations. Health economists will be able to use the QALY values in this study to better evaluate health interventions against COVID-19. Supplementary Information The online version contains supplementary material available at 10.1007/s40271-021-00509-z.

Health-related quality of life and mental well-being of healthy and diseased persons in 8 countries: Does stringency of government response against early COVID-19 matter?

“…The EQ-5D-5L measures five domains of HRQoL during a recall period of today ( Devlin & Brooks, 2017 ). It can be used as an indicator of the Burden of Disease such as Quality-Adjusted Life Years (QALY) ( Poteet & Craig, 2021 ). The EQ-5D-5L includes five dimensions: Mobility (MO), Self-Care (SC), Usual activities (UA), Pain/Discomfort (PD), and Anxiety/Depression (AD).…”

Long-term health-related quality of life in non-hospitalised COVID-19 cases with confirmed SARS-CoV-2 infection in England: Longitudinal analysis and cross-sectional comparison with controls

“…Previous studies on the QALYs lost in COVID-19 cases have been limited and focussed on the acute illness [31]. Compared to previous studies on the H1N1pdm2009 pandemic influenza virus, our estimates are higher than the estimated mean of 2.9 (range: 0-9.9) QALDs lost in laboratory-confirmed influenza cases in the UK [12] and of 3.3 (95% CI, 2.6–4.0) QALDs lost in Spain [11].…”

A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine

“…Evidence related to health utility for COVID-19 is currently limited but rapidly emerging [ 29 ]. Given the lack of evidence at the time of writing, we identified utility impacts of similar conditions.…”